Format

Send to

Choose Destination
Cold Spring Harb Perspect Med. 2014 Jul 1;4(7):a013581. doi: 10.1101/cshperspect.a013581.

Advanced treatment for basal cell carcinomas.

Author information

1
Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305.

Abstract

Basal cell carcinomas (BCCs) are very common epithelial cancers that depend on the Hedgehog pathway for tumor growth. Traditional therapies such as surgical excision are effective for most patients with sporadic BCC; however, better treatment options are needed for cosmetically sensitive or advanced and metastatic BCC. The first approved Hedgehog antagonist targeting the membrane receptor Smoothened, vismodegib, shows remarkable effectiveness on both syndromic and nonsyndromic BCCs. However, drug-resistant tumors frequently develop, illustrating the need for the development of next-generation Hedgehog antagonists targeting pathway components downstream from Smoothened. In this article, we will summarize available BCC treatment options and discuss the development of next-generation antagonists.

PMID:
24985127
PMCID:
PMC4066644
DOI:
10.1101/cshperspect.a013581
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center